Get the Stockscreener App
3.18
3.34%
-0.11
After Hours:
3.20
0.02
+0.63%
Recursion Pharmaceuticals Inc stock is traded at $3.18, with a volume of 15.41M.
It is down -3.34% in the last 24 hours and up +8.53% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.29
Open:
$3.27
24h Volume:
15.41M
Relative Volume:
1.01
Market Cap:
$1.69B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.6452
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
-1.24%
1M Performance:
+8.53%
6M Performance:
-24.29%
1Y Performance:
-36.40%
1-Day Range:
$3.16
$3.34
1-Week Range:
$2.95
$3.39
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.18 | 1.75B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Recursion Pharmaceuticals (RXRX) Stock Valuation After AI Drug Discovery And REC-1245 REC-4881 Updates - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed (RXRX) - Seeking Alpha
Recursion Pharmaceuticals Stock (RXRX) Opinions on AI-Driven Drug Discovery Advances - Quiver Quantitative
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX: AI-driven platform advances multiple clinical programs with major data readouts expected soon - TradingView
Recursion Pharmaceuticals (RXRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Here’s Why Recursion Pharmaceuticals (RXRX) is Among the Best Penny Stocks - Insider Monkey
Recursion Pharmaceuticals Stock Surges After Consecutive Losses - asatunews.co.id
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceutica - GuruFocus
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Gibson Christopher - Moomoo
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Insider Sell: Najat Khan Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock - Investing.com UK
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
Recursion Pharmaceuticals CEO Najat Khan sells $84,459 in RXRX stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock By Investing.com - Investing.com Australia
Recursion Pharma director Christopher Gibson sells $144,800 in stock - Investing.com
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Recursion Pharmaceuticals (RXRX) CEO sells 23,588 shares in planned Rule 10b5-1 trade - Stock Titan
Recursion Q1 2026 slides: pipeline advances amid revenue shortfall - Investing.com
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Najat Khan plans Rule 144 sale of Recursion (NASDAQ: RXRX) shares on 05/15/2026 - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After Positive AI Drug Data And Extended Cash Runway - Sahm
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Gibson files Form 144 to sell 40,000 Class A shares (RXRX) - Stock Titan
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Bumpus Namandje - Moomoo
Recursion (RXRX) Climbs 9.5% Ahead of Next Week’s Business Updates - Insider Monkey
9 Stocks Crushing the Market With Surging Returns - Insider Monkey
Insider Sell: Namandje Bumpus Sells Shares of Recursion Pharmace - GuruFocus
10 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Recursion (NASDAQ: RXRX) director sells 30,000 shares under 10b5-1 plan - Stock Titan
RXRX Stock Grinds Higher As Earnings Beat Supports AI Drug Story - timothysykes.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Clinical Proof and AI Platform Advancements - Quiver Quantitative
RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress - StocksToTrade
Recursion Stock Jumps Before Goldman Sachs Event as AI-Drug Trade Gets Fresh Heat - TechStock²
RXRX Stock Climbs As Earnings Beat Extends Cash Runway - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results - Yahoo Finance
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss - Investing.com
Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation - Yahoo Finance
[144] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
JP Morgan Upgrades Recursion Pharmaceuticals (RXRX) - MSN
Earnings call transcript: Recursion Pharmaceuticals beats EPS, revenue miss Q1 2026 - Investing.com Nigeria
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals to present at Goldman Sachs Healthcare Conference on June 9, 2026 - Pluang
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum - simplywall.st
RXRX (NASDAQ) affiliate sales reported: Borgeson sells 230,000 shares in 2026 - Stock Titan
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khan Najat | CEO and President |
Jun 05 '26 |
Sale |
3.58 |
23,588 |
84,459 |
2,175,796 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):